NLRP3 and cardiomyopathy: In addition, phospholipase D2 (PLD2) deletion ameliorates sepsis-induced cardiomyopathy by suppressing cardiomyocyte pyroptosis via the NLRP3/caspase-1/GSDMD pathway (33).